NEW THERAPIES FOR INTRACTABLE HEPATO-BILIARY-PANCREATIC (HBP) MALIGNANCIES AND METASTATIC DISEASES
My area of research is tumor interaction with its microenvironment and its impact on immunosuppression, angiogenesis and treatment resistance. The goal is identifying new cellular and molecular mechanisms of local tumor progression (in liver cancers) and metastatic tumor progression (in other gastrointestinal cancers and in prostate and breast malignancies), and treatment resistance in advanced cancers.
My current research is aimed at identifying and validating targets for combination therapies that will enhance the efficacy and durability of responses of standard immunotherapy. To this end, my group studying the activity in this combinatorial setting of antiangiogenic drugs, antifibrotic drugs or radiotherapy approaches using preclinical studies that reproduce the hallmarks of human cancers. In parallel, we are conducting studies of biomarkers of response in correlative clinical studies in cancer patients (in more than 40 clinical trials to date). My research efforts are currently supported by grants from Federal sources (US Department of Defense/DoD and National Cancer Institute/NCI) and Foundations, and by agreements with Industry partners.
I have authored over 200 publications so far, of which 130+ are original reports, including in basic research journals such as Cell, Nature, Nature Medicine, Nature Biotechnology, Nature Genetics, and Science Translational Medicine, as well as in clinical journals such as the Journal of Clinical Oncology and JAMA Oncology. Over the last 2 decades, I have been invited to present our results at over 200 local, national and international meetings, including in Grand Rounds, Plenary Talks and Keynote Lectures. For my work, I have received several awards, including from the American Association for Cancer Research (AACR), Cancer Research Institute (CRI), International Association for Surgeons, Gastroenterologists and Oncologists (IASGO), and Massachusetts General Hospital (MGH).
I have been serving as chartered or ad-hoc Member, and Chair or co-Chair of NCI, American Cancer Society (ACS), and Belgium FWO Med4 panels since 2012. I have been also active internationally. I am currently serving as the Secretary General of the IASGO. In addition, I am a member of the American Association for the Study of Liver Diseases (AASLD) Liver Fibrosis Special Interest Group (SIG) Global Outreach Committee. I have been an Honorary Member of the Academy of Medical Sciences of Romania since 2012.
I am teaching tumor biology and translational oncology through daily supervision of postdoctoral research fellows, and graduate and undergraduate students. In the past 15 years, I have been teaching in IASGO Postgraduate Courses in USA, Asia, Europe, Asia, Africa and South America, and nationally in ASTRO, ESTRO, and RTOG translational meetings for residents and clinicians and locally in the MIT-HMS HST Program since 2005. I have been coordinating a research exchange student program with University of Muenster, Germany since 2015, and I have been directing an Annual Course titled “Methods in Biomedical Engineering, Tumor Biology and Immunology” at MGH since 2004.
I obtained a DMD from the University of Medicine Iasi, Romania in 1993, and earned a PhD in Medical Sciences (Gastrointestinal Surgery) from Tohoku University Graduate School of Medicine, Sendai, Japan in 2001. After graduation, I pursued postdoctoral training with Professor Rakesh K. Jain in the Steele Laboratories for Tumor Biology, Department of Radiation Oncology, MGH and Harvard Medical School in Boston. I became a Junior Faculty member (Instructor) in 2004, and then rose through the ranks to Full Investigator at MGH Research Institute in 2016 and Associate Professor of Tumor Biology (Radiation Oncology) at Harvard Medical School in 2012. In 2016, I was appointed as the Director of Translational Research in Gastrointestinal Radiation Oncology at MGH.
(For more information, see full CV at: steele.mgh.harvard.edu/data/research_statements/2/Duda_HMS_CV.pdf)